Academician Huang Xiaojun of PKU People’s Hospital Wins “Shulan Medical Award”
On December 7, 2024, the 11th awarding ceremony of the prestigious “Shulan Medical Award” was held in Hengqin, a new highland of economical integration between Macao and the mainland. Professor Huang Xiaojun, member of the Chinese Academy of Engineering, Director of Peking University Hematology Institute, and Director of Department of Hematology, Peking University People’s Hospital, was honored with the “Shulan Medical Award”.
Academicians Chen Zhu and Li Lanjuan presenting the award to Academician Huang Xiaojun
The “Shulan Medical Award” was initiated in 2014, aiming to recognize outstanding scientific and technological talents of Chinese nationality (including Hong Kong, Macao and Taiwan) who have made original breakthroughs and innovations in the field of medicine and health which have been proved by practice to be scientific and effective. After more than ten years of development, the Award has become a model of high-end talent awards in China’s medical and health community for its strict requirements for nomination, high-level panel judges, standardized procedures for selecting the best, and always maintaining an authoritative and credible selection record.
Name card of the expert
Academician Huang Xiaojun
Professor, Chief Physician, hematologist, member of the Chinese Academy of Engineering. He is currently the director of Peking University Hematology Institute and the director of the National Clinical Research Center for Hematological Diseases. In the past forty years of medical practice, Academician Huang Xiaojun has created the world’s first non-in vitro T-cell-depleted haploidentical (half-matched) hematopoietic stem cell transplantation system, known as “Beijing Protocol”, which has basically solved the world’s medical problem of shortage of hematopoietic stem cell transplant donors and led the world into a new historical era when “everyone has a hematopoietic stem cell transplant donor”. The “Beijing Protocol” has now become the prime model of hematopoietic stem cell transplantation in China and half of the world, which has promoted the great progress of bone marrow transplantation in the past twenty years.
Written by: Lang Lang
Edited by: Liu Xin
Source: PKU Hematology Institute